Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
RIPK3 is essential in modulating TNF-induced beta cell death in TD1 mouse models (Huang et al
Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial
(JCEM, 2006, PMID: 16352683) confirmed dose-dependent GH elevation in healthy adults
References Novartis ianalumab first drug to reduce disease activity and patient burden in Sjgrens disease Phase III trials, 29 October 2025, Novartis, Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients with Active Sjogrens Syndrome (NEPTUNUS-1), ClinicalTrials.gov ID NCT05350072, Abstract Number: LB24: Ianalumab demonstrates significant reduction in disease activity in patients with Sjgrens disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2), American College of Rheumatology, A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome
Michael Lincoff told an audience at the American Heart Association conference in Philidelphia today
